|Mr. Michael F. Kanan||Sr. VP & CFO||477.05k||N/A||1963|
|Mr. Phillandas T. Thompson||Sr. VP, Gen. Counsel & Corp. Sec.||450.38k||N/A||1974|
|Mr. Gregory J. Divis||VP of Corp. and Bus. Devel.||486.93k||N/A||1965|
|Ms. Sandra L. Hatten||Sr. VP of Quality & Regulatory Affairs||380.79k||N/A||1957|
|Mr. Gregory J. Divis Jr.||CEO & Director||N/A||N/A||1967|
Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Avadel Pharmaceuticals plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.